Akebia Therapeutics, Inc. (NASDAQ:AKBA) is set to announce second quarter earning results on Monday 10th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, AKBA to report 2Q20 loss of $ 0.5 per share.
For the full year, analysts anticipate top line of $ 322.68 million, while looking forward to loss of $ 1.59 per share bottom line.
Previous Quarter Performance
Akebia Therapeutics, Inc. revealed loss for the first quarter of $ 0.47 per share, from the revenue of $ 88.48 million. The quarterly revenues hiked 9.21 percent compared with the same quarter last year. Wall street analysts are predicting, AKBA to report 1Q20 loss of $ 0.62 per share from revenue of $ 77.48 million. The bottom line results beat street analysts by $ 0.15 or 24.19 percent, at the same time, top line results outshined analysts by $ 11.00 million or 14.20 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Akebia Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of AKBA was $ 10.98, representing a 267.22 % increase from the 52 week low of $ 2.99 and a 19.91 % decrease over the 52 week high of $ 13.71.
The company has a market capital of $ 1.57 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”AKBA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 15th July 2020, maintained by Morgan Stanley at Equal-Weight rating, with $ 12.00 target price.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co.
